Simulation made simple and affordable.
Widely used in safety critical industries since decades, modeling and simulation is now recommended by healthcare regulators as a complement to experiments and trials, to de-risk and accelerate the approval of new drugs and medical devices while reducing the overall R&D costs.
InSilicoTrials platform is a growing collection of easy-to-use models that solve complex problems in many different therapeutic areas, and in any phase of a new medicine or device development.

Are you a computational scientist
and you develop models?

"As simulation is now recommended by regulatory authorities and policy makers to accelerate approval without compromising with patient safety, it is essential to make available advanced simulation tools like ANSYS to the largest possible audience, no matter of their engineering simulation background. is the platform bridging the gap between software providers and clinical consumers."
Thierry Marchal
Global Industry Director Healthcare at ANSYS
"FDA's efforts in modeling and simulation are enabled through multiple collaborations with external parties that provide additional expertise and infrastructure to advance the development of these state-of-the-art technologies." - July 7, 2017 by FDA Voice
Scott Gottlieb
Former Commissioner of the U.S. Food and Drug Administration (FDA)
"QT/TdP Risk Screen is in line with current initiatives aiming to define a new paradigm in cardiac safety like comprehensive in vitro proarrhythmia assay (CiPA), where modeling and simulation of the human cellular ventricular electrophysiology plays a relevant role in the assessment of the proarrhythmic risk of drugs."
Javier Saiz
Full Professor at Universitat Politècnica de València (UPV, Valencia)

Contact Us

Fill in the form below and get more info
about our solutions